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Although it has been demonstrated that NO inhibits the pro-
liferation of different cell types, the mechanisms of its anti-
mitotic action are not well understood. In this work we have
studied the possible interaction of NO with the epidermal growth
factor receptor (EGFR), using transfected fibroblasts which
overexpress the human EGFR. The NO donors S-nitroso-N-
acetylpenicillamine (SNAP), 1,1-diethyl-2-hydroxy-2-nitroso-
hydrazine (DEA-NO) and N-²4-[1-(3-aminopropyl)-2-hydroxy-
2-nitrosohydrazino]butyl´propane-1,3-diamine (DETA-NO) in-
hibited DNA synthesis of fibroblasts growing in the presence of
fetal calf serum, epidermal growth factor (EGF) or EGF plus
insulin, as assessed by [methyl-$H]thymidine incorporation.
Neither 8-bromo-cGMP nor the cGMP-phosphodiesterase in-
hibitor zaprinast mimicked this effect, suggesting that NO is
unlikely to inhibit cell proliferation via a cGMP-dependent
pathway. SNAP, DEA-NO and DETA-NO also inhibited the
INTRODUCTION
NO is synthesized from l-arginine in different cell types and
regulates a diversity of physiological functions [1–6]. Three
distinct NO synthase (NOS) isoenzymes have been identified in
mammals : eNOS and nNOS, constitutively expressed in en-
dothelial cells and neurons respectively generate small amounts
of NO, which acts as an intercellular messenger ; iNOS, on the
other hand, can be induced by pro-inflammatory cytokines in
macrophages and in many other cell types, resulting in a sustained
high output of NO, which leads to tumour cell and micro-
organism cytotoxicity, and also to functional cell modifications
through its interaction with different proteins [7,8].
NO has been shown to arrest cell proliferation. This effect can
be elicited either by exogenous NO, added as a gas or released
from NO donors [9–13], or by endogenous NO on induction of
iNOS in the target cells [14] or in their neighbours [15]. It has
been proposed that activation of guanylate cyclase drives the
anti-proliferative action of NO in smooth-muscle, cerebellar
glial, and vascular endothelial cells [9,11–13]. However, the
increase in intracellular cGMP concentration does not mimick
the anti-mitotic effect of NO in fibroblasts [10], suggesting that
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transphosphorylation of the EGFR and its tyrosine kinase
activity toward the exogenous substrate poly-l-(Glu-Tyr), as
measured in permeabilized cells using [c-$#P]ATP as phosphate
donor. In contrast, 3-[morpholinosydnonimine hydrochloride]
(SIN-1), a peroxynitrite-forming compound, did not significantly
inhibit either DNA synthesis or the EGFR tyrosine kinase
activity. The inhibitory action of DEA-NO on the EGFR tyrosine
kinase was prevented by haemoglobin, an NO scavenger, but not
by superoxide dismutase, and was reversed by dithiothreitol. The
binding of EGF to its receptor was unaffected by DEA-NO. The
inhibitory action of DEA-NO on the EGF-dependent trans-
phosphorylation of the receptor was also demonstrated in intact
cells by immunoblot analysis using an anti-phosphotyrosine
antibody. Taken together, these results suggest that NO, but not
peroxynitrite, inhibits in a reversible manner the EGFR tyrosine
kinase activity by S-nitrosylation of the receptor.
other mechanisms are also involved. In this context, the inhibition
of the enzyme ribonucleotide reductase by NO generated on
induction of iNOS has been well documented in adenocarcinoma
cells [14,16].
The first step in the intricate pathways leading the cell into
mitosis is the activation of membrane-bound growth factor
receptors by their specific ligands. The epidermal growth
factor (EGF) receptor (EGFR), a member of the tyrosine kinase
receptor superfamily [17–19], exhibits two prominent cysteine-
rich domains in its extracellular region and is widely distributed
in different cell types, including fibroblasts. NO has been shown
to regulate the function of some enzymes and cell-signalling
proteins by S-nitrosylation of critical cysteine residues [20–27].
Therefore the EGFR constitutes a possible target for NO effects
on cell proliferation.
We have tested the hypothesis that NO may prevent cell
proliferation by directly inhibiting the EGFR tyrosine kinase
activity, using a fibroblast cell line transfected with a human
EGFR cDNA. The advantages of using these cells are, first, that
NO can be expected to inhibit their growth through cGMP-
independent pathways as occurs in other fibroblasts [10] and,
second, that they overexpress the EGFR, making it easier to
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detect any functional alteration of this receptor. We present here
evidence that NO directly acts on the EGFR, reversibly reacting
with sensitive thiol group(s) and producing inhibition of both its
transphosphorylation and its tyrosine kinase activity toward
exogenous substrates without affecting binding of its ligand.
MATERIALS AND METHODS
Chemicals
The following products were used: [c-$#P]ATP (triethyl-
ammonium salt) (3000–5000 Ci}mmol) from Amersham or ICN
Pharmaceuticals ; ["#&I]EGF (150–200 lCi}lg) and [methyl-
$H]thymidine (40–60 Ci}mmol) from New England Nuclear ; S-
nitroso-N-acetylpenicillamine (SNAP)N-²4-[-1-(3-aminopropyl)-
2-hydroxy-2-nitrosohydrazino]butyl´propane-1,3-diamine
(DETA-NO) and 2,2«-(hydroxynitrosohydrazino)bis-ethanamine
(SPER-NO) from Research Biochemicals International ; 1,1-
diethyl-2-hydroxy-2-nitrosohydrazine (DEA-NO) fromResearch
Biochemicals International or Alexis Corporation; 3-[morpho-
linosydnonimine hydrochloride] (SIN-1) from Alexis Cor-
poration; EGF (from mouse submaxillary glands) from
Upstate Biotechnology or Sigma; Triton X-100, PMSF, 3,3«-
diaminobenzidine (DAB), aprotinin, leupeptin, pepstatin A, Fast
Green FCF, haemoglobin, 8-bromo-cGMP and p-nitrophenyl
phosphate from Sigma; glutaraldehyde, H
#
O
#
and Na
$
VO
%
from Merck; Tween 20 from Bio-Rad; recombinant anti-
phosphotyrosine monoclonal antibody (RC20) conjugated to
horseradish peroxidase from Transduction Laboratories ; PVDF
membranes of 0±45 lm pore size (Immobilon-P2) from Millipore;
culture medium and fetal calf serum (FCS) from Gibco and
2-O-propoxyphenyl-8-azapurin-6-one (zaprinast) from Rhone
Poulenc Rorer. All other chemicals were of analytical grade.
Cell cultures
The EGFR-T17 fibroblast cell line used in this work derives from
NIH 3T3 murine fibroblasts stably transfected with a human
EGFR cDNA, and overexpresses this receptor [28]. The cells
were grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% (v}v) FCS, 2 mM l-glutamine and
40 lg}ml gentamicin, in a humidified atmosphere of 5% (v}v)
CO
#
in air at 37 °C. Cells were counted, after detachment from
the culture dishes, using a Neubauer chamber.
[methyl-3H]Thymidine incorporation
Incorporation of [methyl-$H]thymidine into DNA was performed
in confluent cultures essentially as previously described [29].
Cells grown in 24-well culture plates were washed twice with
Dulbecco’s phosphate-buffered saline (DPBS; 137 mM NaCl,
2±7 mM KCl, 0±9 mM CaCl
#
, 0±5 mM MgCl
#
and 9±5 mM
sodium}potassium phosphate, pH 7±4) and maintained for 24 h
in DMEM with 1% (w}v) BSA in the absence of FCS. After two
washes with DPBS, the cells were incubated for 24 h in 0±5 ml of
DMEM supplemented with 1% (w}v) BSA, 10 nM (0±25 lCi)
[methyl-$H]thymidine and the growth factors or serum to be
studied. The cells were washed twice with DPBS, treated with ice-
cold 10% (w}v) trichloroacetic acid for 10 min, solubilized with
0±2 M NaOH for 24 h, and neutralized with 0±2 M HCl. The
radioactivity incorporated into the acid-insoluble material was
measured using a scintillation counter.
Determination of cell lysis
Cell lysis was tested by measuring the activity of the intracellular
enzyme lactate dehydrogenase in the culture medium, using
pyruvate as substrate and after the oxidation of NADH. Results
were expressed as the cell lesion index as previously described
[30].
Preparation of haemoglobin
To avoid the presence of methaemoglobin (oxidized haemo-
globin), a solution of 1 mM haemoglobin was reduced with
sodium dithionite as described [31]. The preparation was divided
into aliquots, stored under argon at ®70 °C and used within
48 h.
Phosphorylation assays in permeabilized fibroblasts
Cells grown to confluence were gently detached from the culture
flasks using a plastic cell scraper, suspended in DPBS, and
collected by centrifugation in a swinging-bucket rotor at 190 g
max
for 5 min at room temperature. Thereafter the cells were perme-
abilized at 4 °C for 15 min in a medium containing 24 mM Hepes
(sodium salt), pH 7±4, 9±5 mM MgCl
#
, 0±8 mM EGTA, 16 lM
leupeptin, 1±6 mM PMSF, 0±3 mM Na
$
VO
%
and 0±15% (w}v)
Triton X-100, and used for phosphorylation experiments. Stan-
dard phosphorylation assays were performed for 1 min at 37 °C
in the absence and presence of NO donors in a total volume of
100 ll of a medium containing 7±5 mM Hepes (sodium salt),
pH 7±4, 3 mM MgCl
#
, 1 lM EGF (when added), 100 lg}ml poly-
l-(Glu-Tyr), 100 lM Na
$
VO
%
, 0±5 mM PMSF, 5 lM leupeptin,
10–20 ll (1¬10%–5¬10%) permeabilized EGFR-T17 fibroblasts
and 10 lM (2 lCi) [c-$#P]ATP. The reaction was initiated by the
addition of radiolabelled ATP and stopped with ice-cold 10%
(w}v) trichloroacetic acid. The supernatant was discarded after
centrifugation at 14900 g
max
and the pellet was processed for
electrophoresis and autoradiography as described below. Alter-
natively, intact cells were gently detached from the culture flasks,
resuspended in buffer containing 137 mM NaCl, 5 mM KCl,
1 mM Na
#
HPO
%
, 20 mM Tris}HCl, pH 7±4, and 5 mM glucose,
and incubated at 37 °C for 5 min in the absence and presence of
DEA-NO. The cells were centrifuged to remove the NO donor,
permeabilized as described above and used for phosphorylation
assays.
Phosphorylation assays in intact cells
Cells grown to subconfluence in dishes of 3±3 cm diameter were
deprived of FCS overnight, washed twice with 2 ml of DPBS
buffer and incubated at 37 °C for 30–60 min in 1 ml of serum-
free DMEM in the absence and presence of the NO donor.
Thereafter 10 nM EGF was added and the cells were incubated
for 10 min in the same conditions. Controls in the absence of
EGF were also included. Afterwards, the medium was removed
and the cells were lysed with 0±5 ml of an ice-cold buffer
containing 50 mM Hepes (sodium salt), pH 7±4, 100 mM NaCl,
1% (w}v) Triton X-100, 5% (w}v) glycerol, 50 mM NaF,
1 mM Na
$
VO
%
, 10 mM p-nitrophenyl phosphate, 10 mM
EDTA, 1 mM PMSF, 25 lM leupeptin, 1±5 lM aprotinin and
3 lM pepstatin A. The cell lysate (200 ll) was precipitated with
10% (w}v) ice-cold trichloroacetic acid and processed by slab-
gel electrophoresis as described below. The proteins were electro-
transferred to a PVDF membrane for 2 h at 300 mA, fixed
with 0±2% (v}v) glutaraldehyde in TBS buffer (25 mM Tris}HCl,
pH 8, 150 mM NaCl and 2±7 mM KCl), and temporarily stained
with the dye Fast Green to verify that all the tracks contained the
same amount of protein. Thereafter the PVDF membrane was
blocked with 5% (w}v) BSA for 5 h at room temperature and
washed with 0±1% (w}v) Tween 20 in TBS buffer. The phospho-
tyrosine-containing proteins were probed overnight with a
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1:1000 dilution of the RC20 antibody against phosphotyrosine
conjugated to peroxidase, washed first with 0±1% (w}v) Tween
20 in TBS and thereafter with 50 mM Tris}HCl, pH 7±5. Colour
was developed with 1±7 mM DAB and 0±03% (v}v) H
#
O
#
in
25 ml of 50 mM Tris}HCl, pH 7±4. The integrated photo-
densitometric intensity of the phosphorylated EGFR band was
measured using a computer-assisted scanner.
[125I]EGF cross-linkage assays
The reactions were carried out in the absence and presence of NO
donors in 33 ll of a medium containing 15 mM Hepes (sodium
salt), pH 7±4, 6 mM MgCl
#
, 0±5 mM EGTA, 0±2 mM Na
$
VO
%
,
1 mM PMSF, 10 lM leupeptin, 2 nM (0±1 lCi) ["#&I]EGF, in-
creasing concentrations of non-radiolabelled EGF up to 1 lM,
and 10 ll of (2¬10%–2±5¬10%) EGFR-T17 fibroblasts. After
incubation for 1 h at room temperature, 1 mM bis-(N-
hydroxysuccinimide ester) suberate was added and the mixture
was maintained on ice for 15 min. Cross-linkage was stopped by
the addition of 120 mM Tris}HCl, pH 7±4, and the samples were
processed for electrophoresis and autoradiography as indicated
below.
Other analytical procedures
Slab-gel electrophoresis was performed as described by Laemmli
[32] at 12 mA overnight in linear 5–20% (w}v) polyacrylamide
gradient gels in the presence of 0±1% (w}v) SDS at pH 8±3. Gels
were stained with Coomassie Billiant Blue R-250, and dried
under vacuum at 70 °C on Whatman 3MM Chr filter paper.
X-ray films were exposed at ®20 °C for 2–7 days to obtain
autoradiographs. Labelled proteins were quantified by scanning
the films in a photodensitometer. The intensities of the radio-
labelled bands in the autoradiographs were linearly proportional
to the amount of $#P or "#&I in the bands within the exposure
times used. Protein concentration was determined by the method
of Bradford [33] using bovine c-globulin as standard.
RESULTS
NO donors inhibit DNA synthesis by a cGMP-independent
mechanism
A time course study of the rate of [methyl-$H]thymidine in-
corporation by EGFR-T17 fibroblasts in the absence or presence
of insulin, EGF, EGF plus insulin or FCS showed that maximum
levels of DNA synthesis were attained between 16 and 24 h after
the addition of the growth factors (results not shown). Taking
the DNA synthesis obtained in the presence of FCS as 100%, a
typical experiment shows that mean³S.E.M. values were
90³7% (n¯ 4) and 76³6% (n¯ 4) for EGF and EGF plus
insulin respectively. Lower responses were obtained in the
presence of insulin alone (59³4%, n¯ 4) or in the absence of
any exogenously added growth factor (20³2%, n¯ 4).
To test the effect of NO on [methyl-$H]thymidine incor-
poration, several NO donors with different mechanisms of action
were used. SNAP (Figure 1A), DEA-NO (Figure 1B) and SNP
(Figure 1C) inhibited DNA synthesis in a concentration-de-
pendent manner when cells were growing in the presence of FCS,
EGF or EGF plus insulin. In contrast, SIN-1 (Figure 1D), a
peroxynitrite (ONOO−)-forming agent [34], did not significantly
affect DNA synthesis. DETA-NO, another NONOate similar to
DEA-NO, also inhibited [methyl-$H]thymidine incorporation in
a concentration-dependentmanner in the three growth conditions
mentioned above (results not shown). Apparent inhibition con-
stants (K
i
values) for the four active NO donors were in the range
0±3–0±4 mM for SNAP, 3–5 mM for DEA-NO, 0±3–0±4 mM for
Figure 1 NO donors inhibit DNA synthesis in EGFR-T17 fibroblasts
Incorporation of [methyl-3H]thymidine in cells growing for 24 h in the presence of 10% (v/v)
FCS (*), 10 nM EGF (E) or 10 nM EGF plus 1±7 lM insulin (_), in the presence of the
indicated concentrations of SNAP (A), DEA-NO (B), SNP (C) and SIN-1 (D). Data are expressed
as the percentage of the value measured in the absence of NO donors in each experimental
condition and are presented as the mean³S.E.M. from 4 to 12 determinations.
DETA-NO and 0±3 mM for SNP. The inhibitory action of
SNAP, DEA-NO and DETA-NO was slightly more effective
when the fibroblasts were growing in the presence of EGF
than when growing in the presence of FCS. This was also the case
when DEA-NO was tested in the absence of added growth
factors (results not shown). These latter findings are in agreement
with a possible direct effect of NO on the EGFR, since the basal
DNA synthesis observed in the absence of added growth factors
should be due in part to signalling mediated by the overexpressed
EGFR in the absence of ligand. This is consistent with the
observation that the mean³S.E.M. rate of [methyl-$H]thymidine
incorporation in EGFR-T17 fibroblasts in the absence of added
growth factors was 11³1% (n¯ 28) of the value measured in
the presence of FCS, as compared with 5³1% (n¯ 24) and
6³1% (n¯ 24) measured in non-transfected NIH-3T3 and
Swiss-3T3 fibroblasts respectively.
In order to exclude the possibility that cell lysis occurred
during these treatments, we treated the cells with different
concentrations of the NO donors for 24 h and measured the
release of lactate dehydrogenase. SNAP (1 mM), DEA-NO
(5 mM) and SIN-1 (1 mM) did not provoke significant release of
the cytosolic marker enzyme, with mean³S.E.M. cell lesion
indices of 7³8% (n¯ 6), 9³4% (n¯ 6) and 11³6% (n¯ 8)
respectively. In contrast, 10 mM DEA-NO and 1 mM SNP had
an obvious deleterious effect on the integrity of the cells, yielding
mean³S.E.M. cell lesion indices of 57³8% (n¯ 6) and
71³3% (n¯ 8) respectively. Therefore we excluded SNP
altogether from further studies, and DEA-NO was used at
concentrations no higher than 5 mM in the rest of the experiments
performed with intact cells. Furthermore we verified that most
cells remained attached to the culture dishes when non-lytic
concentrations of the NO donors were used. Moreover, cells
were able to recover the capacities of both [methyl-$H]thymidine
incorporation and reaching confluence after the NO donors were
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Figure 2 8-Br-cGMP and zaprinast do not mimic the effect of NO donors
Incorporation of [methyl-3H]thymidine in cells growing for 24 h in the presence of 10% (v/v)
FCS (*), 10 nM EGF (E) or 10 nM EGF plus 1±7 lM insulin (_), and in the presence of
the indicated concentrations of 8-Br-cGMP (A) or zaprinast (B). Data obtained from a typical
experiment performed in quadruplicate are expressed as in Figure 1.
Figure 3 DEA-NO and DETA-NO inhibit the transphosphorylation of the
EGFR and the phosphorylation of poly-L-(Glu-Tyr )
Phosphorylation assays were performed in permeabilized cells in the absence (Control) and
presence of either 1 mM DEA-NO or 1 mM DETA-NO, as indicated, and in the absence (®)
and presence (­) of 1 lM EGF. Arrows point to the phosphorylated 170 kDa EGFR. The dark
smears along the tracks correspond to phosphorylated poly-L-(Glu-Tyr).
removed and the cells were reseeded in fresh medium in the
presence of FCS (results not shown).
A major pathway for NO action involves the activation of
guanylate cyclase, which produces a subsequent increase in the
concentration of intracellular cGMP [1–6]. Therefore we per-
formed experiments to establish whether cGMP plays any role in
the overall process leading to the inhibition of cell proliferation
by NO donors in EGFR-T17 fibroblasts. As shown in Fig. 2(A),
8-Br-cGMP, a cell-membrane-permeant analogue of cGMP, did
not exert any inhibitory effect of DNA synthesis induced by FCS
or EGF, although a slight inhibition (25%) was observed when
cells were growing in the presence of EGF plus insulin. In
contrast, a slight activation was observed in the presence of EGF
alone. Furthermore Figure 2(B) shows that zaprinast, a cGMP-
phosphodiesterase inhibitor, also failed to significantly inhibit
Figure 4 Effect of different concentrations of NO donors on the EGFR
tyrosine kinase activity
Phosphorylation of the EGFR (A, C and E) and poly-L-(Glu-Tyr) (B, D and F) in permeabilized
cells, in the presence of the indicated concentrations of SNAP (A and B), DEA-NO (C and D)
or SIN-1 (E and F) and in the absence (D) and presence (E) of 1 lM EGF. Data are
expressed as the percentage of the values measured in the absence of both EGF and NO donors,
and are presented as the mean³S.D. from two to four experiments.
DNA synthesis induced by FCS, EGF or EGF plus insulin.
These results suggest that cGMP-dependent protein kinases
and}or other cGMP-response elements are unlikely to be essential
for the arrest of the proliferative response induced by NO donors
in EGFR-T17 fibroblasts, as previously shown in non-transfected
fibroblasts [10].
NO donors inhibit the EGFR tyrosine kinase activity
To test the effect of NO on the EGFR tyrosine kinase activity, we
used permeabilized cells to perform in situ assays of both the
transphosphorylation of the receptor and the phosphorylation of
the synthetic substrate poly-l-(Glu-Tyr), using [c-$#P]ATP as the
phosphate donor. Figure 3 shows the phosphorylation of both
the 170 kDa EGFR and poly-l-(Glu-Tyr) in the absence and
presence of EGF (control). As we have reported previously [35],
the indicated 170 kDa phosphopolypeptide was indeed the
EGFR, as demonstrated by immunoprecipitation using a specific
antibody. We have also demonstrated that EGF strongly
stimulates the phosphorylation of tyrosine residues in the EGFR
without significantly affecting the phosphorylation levels of
serine}threonine residues [36], which indicates that the observed
EGF-dependent phosphorylation of the EGFR (the extent of
phosphorylation in the presence minus that in the absence of
EGF) was due to its transphosphorylation. Figure 3 also shows
that the presence of NO donors, either DEA-NO or DETA-NO,
significantly inhibited the transphosphorylation of the EGFR
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Figure 5 SNAP and DEA-NO do not inhibit the binding of EGF to its
receptor
Binding of [125I]EGF to its receptor was measured in the absence of NO donors (D) and in
the presence of 1 mM SNAP (E) or 1 mM DEA-NO (_) at the indicated concentrations of
non-radiolabelled EGF. The plot represents the mean³S.E.M. levels of bound [125I]EGF
expressed as percentage values from three experiments. 100% represents the value measured
in the absence of non-radiolabelled EGF.
and the phosphorylation of poly-l-(Glu-Tyr), particularly in the
presence of EGF. The inhibitory effects on both phosphorylation
processes were also observed with other NO donors, such as
SPER-NO (results not shown) and SNAP (see below).
Using the phosphorylation assay described above, we tested
the effects of different concentrations of SNAP, DEA-NO and
SIN-1 on both the transphosphorylation of the EGFR and its
tyrosine kinase activity toward poly-l-(Glu-Tyr). SNAP inhibited
in a concentration-dependentmanner both the transphosphoryla-
tion of the receptor (Figure 4A) and the phosphorylation of
poly-l-(Glu-Tyr) (Figure 4B) in the absence and presence of
EGF. In the presence of the ligand, the K
i
values for SNAP were
approx. 0±3 mM for the transphosphorylation of the receptor
and 0±7 mM for its tyrosine kinase activity toward the exogenous
substrate. DEA-NO also inhibited in a concentration-dependent
manner both the transphosphorylation of the EGFR (Figure 4C)
and the phosphorylation of poly-l-(Glu-Tyr) (Figure 4D) in the
absence and presence of EGF. We would like to mention that
most of the inhibitory effects of DEA-NO on the EGFR tyrosine
kinase were observed at non-cytolytic concentrations of this
agent (5 mM or lower). In the presence of EGF, K
i
values for
DEA-NO were approx. 1 mM and 2 mM for the trans-
phosphorylation of the EGFR and the phosphorylation of poly-
l-(Glu-Tyr) respectively. On the other hand, SIN-1 exerted no
inhibitory effect on either the transphosphorylation of the EGFR
(Figure 4E) or the phosphorylation of poly-l-(Glu-Tyr) (Figure
4F), in the absence or presence of EGF.
In order to test whether NO inhibits the binding of EGF to its
receptor, we performed ["#&I]EGF-binding experiments in the
absence and presence of NO donors. As shown in Figure 5,
neither SNAP nor DEA-NO affected the binding of ["#&I]EGF to
its receptor. We calculated a dissociation constant (K
d
) of EGF
for its receptor of approx. 20 nM in the absence and presence of
either NO donor.
NO, but not ONOO−, inhibits the EGFR tyrosine kinase activity
To ascertain whether the inhibitory action of DEA-NO was due
to the presence of NO in the medium, we used haemoglobin as
Table 1 Haemoglobin prevents the inhibitory action of DEA-NO
Phosphorylation of the EGFR and poly-L-(Glu-Tyr) was assayed in permeabilized cells, in the
absence and presence of 5 mM DEA-NO, and in the absence and presence of 1 lM EGF as
indicated. The assays were performed in the absence and presence of 5 lM haemoglobin. Data
are expressed as the percentage of the values measured in the absence of both EGF and NO
donor in the absence or presence of haemoglobin and represent the mean³S.E.M. from four
experiments.
Phosphorylation (%)
EGFR Poly-L-(Glu-Tyr)
Addition ®EGF ­EGF ®EGF ­EGF
None 100 215³52 100 187³41
DEA-NO 52³9 86³31 83³24 85³30
Haemoglobin 100 181³68 100 192³25
DEA-NO­haemoglobin 48³8 187³64 72³10 129³17
Table 2 Inhibitory action of DEA-NO in the presence of SOD
Phosphorylation of the EGFR and poly-L-(Glu-Tyr) was assayed in permeabilized cells, in the
absence and presence of 5 mM DEA-NO and/or 15 units/ml SOD, both in the absence and
presence of 1 lM EGF, as indicated. Data are expressed as the percentage of the values
measured in the absence of both EGF and NO donor and represent the mean³S.E.M. or the
mean³range for duplicate values, from the number of experiments indicated in parentheses.
Phosphorylation (%)
EGFR Poly-L-(Glu-Tyr)
Addition ®EGF ­EGF ®EGF ­EGF
None 100 246³59 (3) 100 211³68 (2)
DEA-NO 56³13 (3) 103³37 (3) 81³38 (2) 96³34 (2)
SOD 80³19 (3) 287³73 (3) 69³21 (3) 218³61 (2)
DEA-NO­SOD 29³8 (3) 134³27 (3) 40³11 (3) 45³5 (2)
a scavenger of this compound. Table 1 shows that DEA-NO in
the absence of haemoglobin inhibited the transphosphorylation
of the EGFR and the phosphorylation of poly-l-(Glu-Tyr), more
significantly in the presence than in the absence of EGF. In
contrast, the presence of haemoglobin completely prevented the
inhibitory action of DEA-NO on the transphosphorylation of
the EGFR in the presence of EGF. Haemoglobin was somewhat
less effective in preventing the inhibitory action of DEA-NO on
the phosphorylation of poly-l-(Gly-Tyr).
To exclude the possibility that the observed inhibition of the
EGFR tyrosine kinase activity by DEA-NO could be due to the
presence of ONOO−, a product of the reaction of NO with O
#
−d,
we performed similar phosphorylation experiments in the pres-
ence of superoxide dismutase (SOD). This enzyme should prevent
the accumulation of O
#
−d required for the formation of ONOO−.
Table 2 shows that DEA-NO inhibited both the trans-
phosphorylation of the EGFR and the phosphorylation of poly-
l-(Glu-Tyr) in the absence and presence of SOD and both in the
absence and presence of EGF. Notably, the inhibitory action of
DEA-NO on the phosphorylation of poly-l-(Glu-Tyr) was even
more effective in the presence of SOD.
Inhibitory action of NO is reversible
To establish whether NO inhibits the EGFR tyrosine kinase
activity by modifying thiol groups on the receptor, we attempted
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Table 3 DTT partially reverses the inhibition produced by DEA-NO
Whole cells were incubated in the absence and presence of 5 mM DEA-NO. Thereafter the NO
donor was removed by centrifugation, the cells were permeabilized and phosphorylation of the
EGFR and poly-L-(Glu-Tyr) was assayed in the absence or presence of 1 lM EGF, after
incubation for 1 min at 37 °C in the absence or presence of 1 mM DTT. Data are expressed
as the percentage of the values measured in the absence of both EGF and NO donor and
represent the mean³S.E.M. from three experiments.
Phosphorylation (%)
EGFR Poly-L-(Glu-Tyr)
Addition ®EGF ­EGF ®EGF ­EGF
None 100 189³26 100 135³19
DEA-NO 38³7 62³13 30³5 40³4
DTT 103³9 183³33 106³3 130³14
DEA-NO­DTT 62³7 159³21 43³4 70³7
Figure 6 NO inhibits the transphosphorylation of the EGFR in intact cells
Serum-deprived cells were incubated in DMEM in the absence and presence of 5 mM DEA-NO
(as indicated) for 30 min. Thereafter the cells were stimulated for 10 min with 10 nM EGF (as
indicated), lysed and treated with ice-cold 10% (w/v) trichloroacetic acid. The lysates were
processed by electrophoresis and the levels of tyrosine phosphorylation of the receptor were
measured by immunoblot analysis as described in the Materials and methods section.
to reverse this inhibition using a reducing agent. Whole intact
cells were incubated in the absence and presence of 5 mM DEA-
NO for 5 min and, after centrifugation to remove most of the
DEA-NO, phosphorylation assays were performed in perme-
abilized cells. Table 3 shows thatDEA-NOpretreatment inhibited
the EGF-induced transphosphorylation of the EGFR and the
phosphorylation of poly-l-(Glu-Tyr). Addition of dithiothreitol
(DTT) to the assay system did not modify the tyrosine kinase
activity of the EGFR in untreated cells in either the absence or
presence of EGF. DTT, however, re-activated the EGF-induced
transphosphorylation of the EGFR and the phosphorylation of
poly-l-(Glu-Tyr) in cells treated with DEA-NO. The re-ac-
tivation of the transphosphorylation of the EGFR was more
pronounced than the re-activation of the tyrosine kinase activity
toward poly-l-(Glu-Tyr). Interestingly, removal of DEA-NO
before the addition of DTT was an essential requirement to
detect re-activation of the EGFR tyrosine kinase activity. When
DEA-NO was present during the phosphorylation assays, the re-
activation induced by DTT was not observed (results not shown).
NO inhibits the transphosphorylation of the EGFR in intact cells
To ascertain whether the inhibitory action of NO also occurs in
intact cultured cells, we tested the effect of DEA-NO on the
transphosphorylation of the EGFR in serum-deprived cells as
measured by immunoblot analysis using an antibody against
phosphotyrosine. Figure 6 shows that a short stimulation with
EGF induces the transphosphorylation of the receptor in control
non-treated cells. However, a strong inhibition of this trans-
phosphorylation was observed in cells treated with 5 mM DEA-
NO. The densitometric measurement of the intensity of the
EGFR band in different immunoblots shows that the
mean³S.E.M. inhibition of the EGFR transphosphorylation
was 69³12% (n¯ 4) in the presence of DEA-NO.
DISCUSSION
Our results show that NO donors inhibit the EGFR tyrosine
kinase activity in cultured fibroblasts, and that this phenomenon
correlates well with their anti-proliferative effect in the same
cells. NO exerted an anti-mitotic action, since both SNAP and
the NONOates (DEA-NO and DETA-NO), which release NO
by different mechanisms [37], inhibited DNA synthesis in a
reversible manner and without inducing significant cell lysis. As
previously shown in non-transfected fibroblasts [10], the anti-
proliferative action of NO detected by us was not mediated by
guanylate cyclase, because the enhancement of intracellular
cGMP concentration did not significantly inhibit DNA synthesis.
Also, the effect of NO donors was not the result of ONOO−
formation, as can be concluded from the absence of any anti-
mitotic effect of SIN-1. Although the inhibition of DNA synthesis
was observed in all growth conditions tested (EGF, EGF plus
insulin, FCS and absence of added growth factors), the sensitivity
to NO donors was somewhat higher when either EGF was the
only growth factor used or in the absence of exogenous growth
factors. All these results were compatible with the hypothesis of
a possible direct effect of NO on the EGFR molecule.
To test this possibility, the effects of NO donors on the EGFR
tyrosine kinase activity were assayed. SNAP and DEA-NO, as
well as two other NONOates, DETA-NO and SPER-NO,
inhibited the EGF-induced phosphorylation of both the EGFR
and the exogenous substrate poly-l-(Glu-Tyr), with K
i
values
similar to those observed in [methyl-$H]thymidine incorporation
experiments. Furthermore SIN-1 had no effect on the EGFR
tyrosine kinase activity. The inhibition of the EGFR tyrosine
kinase by NO donors observed in permeabilized fibroblasts
exclude the participation of cGMP in the receptor inhibition,
since soluble cytoplasmic components are highly diluted in the
incubation medium on permeabilization, strongly suggesting a
direct interaction of NO with the receptor protein. The possibility
of NO inducing activation of a phosphotyrosine protein phos-
phatase, which would also result in a decreased phosphorylation
of the EGFR and of poly-l-(Glu-Tyr), can be excluded because
orthovanadate, a protein-phosphotyrosine phosphatase inhibitor
[38], was always present in the phosphorylation assays. It is
interesting to note that DEA-NO also inhibited the trans-
phosphorylation of the EGFR in intact cells, supporting the
physiological relevance of this process.
The active species inhibiting the EGFR tyrosine kinase activity
was indeed NO, since the effects of DEA-NO were prevented by
the NO scavenger haemoglobin. Haemoglobin protected in full
the transphosphorylation of the EGFR, although it only partially
prevented the inhibitory action of DEA-NO on the phosphoryla-
tion of poly-l-(Glu-Tyr). The reasons for this discrepancy are at
present unclear.
NO rapidly reacts with O
#
−d in aqueous solutions, yielding
ONOO−, a highly reactive agent with cytotoxic effects [20].
Among other reactions, ONOO− is responsible for the nitration
of tyrosine residues in proteins, which would result in decreased
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phosphorylation [39,40]. However, our results suggest that the
inhibition of the EGFR tyrosine kinase by NO does not involve
ONOO− formation. First, as mentioned above, the inhibition of
EGFR and poly-l-(Glu-Tyr) phosphorylation was not observed
when SIN-1 was used as the source of NO. Secondly, the EGFR
tyrosine kinase inhibition induced by DEA-NO also occurred in
the presence of SOD, conditions under which the formation of
any significant amount of ONOO− should be prevented.
A mechanism for the NO action on the EGFR could be the
redox reaction of the gas with critical thiol group(s) of the
receptor, leading to its S-nitrosylation. Nitrosylation of thiol
groups has been shown to modulate the activity of certain
enzymes [23,25,27] and membrane-associated proteins such as N-
methyl-d-aspartate receptors [22], Ca#+-dependent K+ channels
[24] or the G-protein Ras [26], and is at present considered to be
a mechanism with broad regulatory implications [20]. DTT
completely re-activated the EGF-dependent phosphorylation
(the amount of phosphorylation in the presence minus that in the
absence of EGF) of the EGFR and poly-l-(Glu-Tyr) when
added to cells pretreated with an NO donor, suggesting that thiol
groups in the EGFR were indeed involved in the inhibition
process. The importance of active thiol groups for the EGFR
tyrosine kinase is supported by the observation that the thiol
group reagent N-ethylmaleimide strongly inhibits this activity
(results not shown). However, the re-activation of the EGFR by
DTT in the absence of EGF was not complete, particularly in the
case of the exogenous substrate, suggesting that poly-l-(Glu-
Tyr)might also be phosphorylated by other NO-sensitive tyrosine
kinases not re-activated by the reducing agent. We propose that
the EGFR is probably S-nitrosylated, resulting in conformational
changes in the receptor molecule leading to inhibition of its
tyrosine kinase activity, and without affecting the affinity or the
maximum binding capacity for its ligand.
Although the concentrations of NO donors necessary to
produce anti-proliferative effects in different cell types [9–11] or
S-nitrosylation of different proteins [22,23,26,41–44] may appear
too high to have physiological significance, considering the
kinetics of NO release by these drugs [37] together with the low
solubility and short half-life of NO itself [8], the resulting NO
concentrations are probably close to those present in the tissues
when NO is synthesized by iNOS [45]. Consequently, the
regulation of the EGFR by NO might occur in io on induction
of iNOS. This is supported by the fact that the anti-proliferative
action of endogenous NO becomes apparent only when iNOS is
expressed, either in cells treated with cytokines [14,15] or in
engineered cells [46]. On the other hand, it has been demonstrated
that EGF inhibits the expression of iNOS [47]. Therefore complex
feedback mechanisms are likely to operate in io between EGF
and endogenous NO to control cell proliferation.
Recently, NO has been reported to inhibit EGF-mediated
phosphoinositide hydrolysis and the subsequent increase in
cytosolic free Ca#+ in EGFR-T17 fibroblasts as well as other cells
[48]. However, these actions do not seem to be derived from the
direct inhibition of the EGFR tyrosine kinase activity demon-
strated in this work, since they were prevented by a cGMP-
dependent protein kinase I inhibitor [48]. Thus NO appears to
inhibit several different components of the signal-transduction
pathways initiated by EGFR activation.
The specific thiol group(s) of the EGFR sensitive to NO have
not yet been identified. However, it is tempting to speculate that
the two prominent cysteine-rich domains in its extracellular
region may constitute antennas for NO. Other members of the
tyrosine kinase superfamily of receptors also have cysteine-rich
domains [19]. Therefore the study of the effects of NO on other
growth factor receptors with tyrosine kinase activity should help
to unravel the mechanisms of action of this regulator on the
initial steps of cell proliferation signalling.
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